Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03170999
Other study ID # 201098
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 29, 2018
Est. completion date May 29, 2020

Study information

Verified date July 2020
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It has been observed that COPD exacerbations are under-reported in China. One of the reasons for this is Chinese subjects with COPD cannot describe the symptoms of exacerbation mentioned in English. Hence this study aims to create a tool called CERT that will help Chinese physicians and subjects with COPD to recognize and report exacerbations. The study will be carried out in 4 stages: item identification, cognitive briefing, item reduction and creation of final CERTs. Two CERTs will be prepared, one for subjects with COPD and another for physicians. A total of approximately 200 subjects will be included in the study and each subject will contribute to only one step.


Recruitment information / eligibility

Status Completed
Enrollment 199
Est. completion date May 29, 2020
Est. primary completion date May 29, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Male or female of age greater than or equal to 40 years.

- Spirometrically confirmed COPD according to diagnostic criteria in Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016.

- A treated exacerbation of COPD within 3 months prior to the study visit.

- Willing and able to provide informed consent, and able to participate in focus groups or cognitive interviews.

- Literacy is not a requirement for any of the groups.

Exclusion Criteria:

- Current diagnosis of asthma or clinically relevant bronchiectasis. Note: Subjects with Asthma COPD Overlap Syndrome (ACOS) are eligible.

- Subjects with a concurrent significant, uncontrolled, active medical condition or disease state of other organ diseases or systematic diseases; psychiatric condition; cognitive impairment or any other reasons that in the investigator's opinion, would place subjects at risk or interfere with study evaluation or affect participation in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Focus group interview
Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
Draft item set
Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
Candidate item set
Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.

Locations

Country Name City State
China GSK Investigational Site Chongqing
China GSK Investigational Site Hangzhou Zhejiang
China GSK Investigational Site Shenyang

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary COPD symptom item set to identify common phrases of COPD exacerbation The most frequently used items to describe the symptomatic characteristics of the onset of an exacerbation will be identified from COPD symptom item set. Day 1
Primary Preparation of COPD Exacerbation Recognition tool (CERT) Two simple educational hand-outs called CERT will be prepared, one for the subjects with COPD and the other for the physicians which will help Chinese physicians and subjects in recognizing and reporting COPD exacerbations. Day 1
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04506346 - Risk Prediction of Difficult Tracheal Intubation in OSAHS Patient
Completed NCT02106143 - RejuvenAirâ„¢ System Lobectomy Safety and Histology Study N/A
Completed NCT03274791 - Clinical Features and Airways Inflammation in Never Smokers and Smokers With COPD N/A
Completed NCT01765530 - Efficacy Study of a Novel Device to Clean the Endotracheal Tube N/A
Completed NCT01721486 - Acetaminophen's Efficacy For Post-operative Pain Phase 4
Completed NCT03656315 - Scoring System to Predict Depth of Cricothyroid Membrane N/A
Recruiting NCT05880836 - In Line Aerosol Nebulization With High Flow N/A
Recruiting NCT05573919 - VivAer: A Correlation Between Symptom Scores and Objective Findings N/A
Completed NCT02403934 - Jaw Elevation Device in Deep Sedation Study N/A
Recruiting NCT00452062 - Dexamethasone and the Prevention of Post-Extubation Airway Obstruction in Adults Phase 2
Completed NCT02563210 - Airway Resistance Measurement in Children 3 to 6 Years of Age N/A
Completed NCT03488849 - SureCRIC Standardized Patient Study
Completed NCT03752593 - The Incidence of Difficult Intubation in Obese Versus Non-obese Patients
Recruiting NCT05974488 - The Efficacy of Distal Pharyngeal Airway for Oxygenation During TEE N/A
Not yet recruiting NCT02975791 - Ultrasonography Versus Palpation for Identification of the Cricothyroid Membrane N/A
Completed NCT00788788 - Heliox in Experimental Upper Airway Obstruction Phase 1/Phase 2
Not yet recruiting NCT06128811 - Dental Isolation Systems Among Pediatric Patients With Different Airway Patency N/A
Completed NCT05550220 - A Modified Cuff Leak Test and Reintubation in Mechanically Ventilated Patients N/A
Completed NCT03165461 - Evaluation of the Use of Tracheal Intubation Through a Laryngeal Tube to Intubate Anesthetized Patients
Recruiting NCT03969147 - Investigation of a Novel Oropharyngeal Airway: The ManMaxAirway N/A